The Sixth Batch of national centralized drug procurement will be opened soon. At 10 a.m. on November 26, this centralized purchase will also officially enter the stage of declaration information disclosure. Beijing Youth Daily reporter learned that this gathering targeted at diabetes treatment drugs insulin. According to the public information, this is the first time that insulin has entered the national collection, and it is also the first time that biological drugs have entered the national collection. According to the national centralized drug procurement document (insulin special) (gy-yd2021-3) previously issued by the joint drug procurement office of the state organization, the varieties of this centralized drug procurement include meal human insulin, basic human insulin, premixed human insulin, meal insulin analogues, basic insulin analogues and premixed insulin analogues, with a total of 6 procurement groups. The varieties participating in this round of national collection are subject to the maximum application price limit. The maximum effective application price of meal, basic and premixed human insulin is 50 yuan per piece, the maximum effective application price of meal and premixed insulin analogues is 72 yuan per piece, and the maximum effective application price of basic insulin analogues is 132 yuan. Specifically, the listed drugs that belong to the scope of centralized drug procurement and have obtained valid domestic registration approval before November 14, 2021 are qualified to participate in this round of national procurement if their quality meets the standards of relevant national departments and the products produced according to the requirements of relevant departments. In addition to meeting the above requirements, the enterprises participating in the bidding also need to meet the centralized procurement requirements in terms of quality standards, production capacity, supply stability and enterprise credit. According to the analysis of Dongguan Securities Research Report, there are 81 varieties collected this time. Specifically, there are 43 second-generation insulin, accounting for 53%, and 38 third-generation insulin, accounting for 47%. The largest number of varieties is the premixed human insulin product group (18 varieties), and the least is the two product groups of basic insulin and premixed insulin analogues, both of which have only 12 varieties. From the perspective of enterprises, local and foreign enterprises are basically the same, with 41 Local and 40 foreign enterprises. (outlook new era)